ReviewInternational journal of biological sciences2020
Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2.
Review in International journal of biological sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04513158 (Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2), which is not on this map. Cited by 162 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection
Who cites it
162 citing papers in PubMed, 1 synthesis or guideline pooled it, 281 citations in OpenAlex.
- Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review.International immunopharmacology · 2020Pooled it
- Early mortality benefit with COVID-19 convalescent plasma: a matched control study.British journal of haematology · 2021Trial
- Antibodies response in symptomatic and asymptomatic SARS-CoV-2 infected persons in Thailand.PloS one · 2025Article
- Innate immune response in COVID-19: single-cell multi-omics profile of NK lymphocytes in a clinical case series.Cell communication and signaling : CCS · 2024Article
- Article
- From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2.Vaccines · 2024Review
- Graph Convolutional Network for predicting secondary structure of RNA.Research square · 2024Article
- Distinct Functional Humoral Immune Responses Are Induced after Live Attenuated and Inactivated Seasonal Influenza Vaccination.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Differences in syncytia formation by SARS-CoV-2 variants modify host chromatin accessibility and cellular senescence via TP53.Cell reports · 2023Article
- Analysis of the prevalence of anti-SARS-CoV-2 antibodies in groups of medical and non-medical professions.International journal of occupational medicine and environmental health · 2023Article
- Recent Progress in Antibody Epitope Prediction.Antibodies (Basel, Switzerland) · 2023Review
- Article
- ARPIP: Ancestral Sequence Reconstruction with Insertions and Deletions under the Poisson Indel Process.Systematic biology · 2023Article
- A point-of-care biosensor for rapid detection and differentiation of COVID-19 virus (SARS-CoV-2) and influenza virus using subwavelength grating micro-ring resonator.Applied physics reviews · 2023Article
- Density estimation of SARS-CoV2 spike proteins using super pixels segmentation technique.Applied soft computing · 2023Article
- Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications.Frontiers in immunology · 2023Review
- Factors influencing plasma donation behavior of COVID-19 recovered patients in Bangladesh: A pilot study.Health science reports · 2023Article
- Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses.Biomedical engineering advances · 2022Review
- Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine.International immunopharmacology · 2022Review
- A computational approach to rapidly design peptides that detect SARS-CoV-2 surface protein S.NAR genomics and bioinformatics · 2022Article
102 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A newly identified novel coronavirus (SARS-CoV-2) is causing pneumonia-associated respiratory syndrome across the world. Epidemiology, genomics, and pathogenesis of the SARS-CoV-2 show high homology with that of SARS-CoV. Current efforts are focusing on development of specific antiviral drugs. Therapeutic neutralizing antibodies (NAbs) against SARS-CoV-2 will be greatly important therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19). Herein, the host immune responses against SARS-CoV discussed in this review provide implications for developing NAbs and understanding clinical interventions against SARS-CoV-2. Further, we describe the benefits, challenges and considerations of NAbs against SARS-CoV-2. Although many challenges exist, NAbs still offer a therapeutic option to control the current pandemic and the possible re-emergence of the virus in the future, and their development therefore remains a high priority.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.